Patent ID: 9616107
Date: 2017-04-11
CPC Classifications: A61K,A61M,A61P

Claim:
1. A method, comprising the steps of: continuously administering a natriuretic peptide to a subject suffering from kidney disease alone, heart failure alone, or with concomitant kidney disease and heart failure or cardiorenal syndrome using a drug provisioning component to chronically deliver a therapeutically effective amount of the natriuretic peptide to the subject at a rate which maintains a subject-specific mean steady state plasma concentration, and maintaining the plasma concentration of the natriuretic peptide within a specified range, wherein the specified range is pre-determined by administering a test dose of the natriuretic peptide to the subject so that the specified range is not greater than a plasma concentration of the natriuretic peptide reached in the subject during either a subcutaneous bolus at 18,000 ng/kg or a 1 hour intravenous infusion of the natriuretic peptide at 300 ng/(kg·min) based on the subject's body weight, and wherein the drug provisioning component delivers the natriuretic peptide subcutaneously for multiple days.